{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:34:21Z","timestamp":1790231661051,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031551","name":"Hospital das Cl\u00ednicas, Faculdade de Medicina de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008353","name":"Funda\u00e7\u00e3o de Apoio ao Ensino, Pesquisa e Assist\u00eancia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.gastrohep.2025.502396","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:54:31Z","timestamp":1740167671000},"page":"502396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-na\u00efve patients with ulcerative colitis: A comparative real-world multicentric observational study"],"prefix":"10.1016","volume":"48","author":[{"given":"Sandro","family":"da Costa Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rog\u00e9rio Serafim","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia Yukie","family":"Sassaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel Luz","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munique Kurtz","family":"de Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Andrade","family":"Chebli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Lu\u00eds","family":"Luporini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Jos\u00e9 Tiburcio","family":"Alves Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Jorge","family":"Firmino N\u00f3brega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno C\u00e9sar","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eron F\u00e1bio","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel Botelho","family":"Quaresma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Mattioli","family":"Nicollelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Galhardi","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata de Medeiros","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juarez Roberto de Oliveira","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia da Concei\u00e7\u00e3o","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00e9la Oliveira","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello Rabello","family":"Imbrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Kibune","family":"Nagasako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"F\u00e9res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Ernesto de Almeida","family":"Troncon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Gustavo","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falio Maria Fonseca","family":"Chebli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2025.502396_bib0150","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5152\/tjg.2022.21124","article-title":"Factors predictive of proximal disease extension and clinical course of patients initially diagnosed with ulcerative proctitis in an IBD referral center","volume":"33","author":"da Costa Ferreira","year":"2022","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0160","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.3748\/wjg.v25.i38.5862","article-title":"Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil","volume":"25","author":"Parra","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0165","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0170","doi-asserted-by":"crossref","first-page":"100863","DOI":"10.1016\/j.scrs.2022.100863","article-title":"Medical treatment of ulcerative colitis","volume":"33","author":"Bhattacharya","year":"2022","journal-title":"Semin Colon Rectal Surg"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0175","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: a meta-analysis of population-based cohorts","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0185","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-016-0676-y","article-title":"Mucosal healing in ulcerative colitis: a comprehensive review","volume":"77","author":"Boal Carvalho","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0195","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14740\/gr934w","article-title":"Comparative effectiveness of vedolizumab vs. infliximab induction therapy in ulcerative colitis: experience of a real-world cohort at a Tertiary Inflammatory Bowel Disease Center","volume":"11","author":"Allamneni","year":"2018","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0205","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41598-023-28907-3","article-title":"Vedolizumab is superior to infliximab in biologic na\u00efve patients with ulcerative colitis","volume":"13","author":"Sablich","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.07.038","article-title":"Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis","volume":"20","author":"Narula","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0215","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cgh.2020.10.003","article-title":"Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis","volume":"20","author":"Lukin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0220","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0225","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"26","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0230","first-page":"330","article-title":"Review of the landmark VARSITY trial","volume":"17","author":"Feagan","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.17616","article-title":"Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-na\u00efve patients with ulcerative colitis: a two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD-study","volume":"58","author":"Bokemeyer","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"supplement_1","key":"10.1016\/j.gastrohep.2025.502396_bib0240","doi-asserted-by":"crossref","first-page":"S019","DOI":"10.1093\/ecco-jcc\/jjx180.025","article-title":"OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis","volume":"12","author":"Faleck","year":"2018","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0245","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0250","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221080793","volume":"15","author":"Pudipeddi","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0255","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.3390\/jcm12134488","article-title":"Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe ulcerative colitis: long-term real-world cohort data","volume":"12","author":"Konikoff","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0260","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820941179","article-title":"Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland","volume":"13","author":"Petryszyn","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0265","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/apt.16160","article-title":"Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme","volume":"53","author":"Danese","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0270","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12876-020-01332-w","article-title":"Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review","volume":"20","author":"Helwig","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0275","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.15177","article-title":"Comparative safety and effectiveness of tumor necrosis factor \u03b1 antagonists and vedolizumab in elderly IBD patients: a multicentre study","volume":"49","author":"Adar","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0280","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/apt.15921","article-title":"Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease","volume":"52","author":"Bohm","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0285","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.cgh.2021.02.032","article-title":"Comparative risk of serious infections with tumor necrosis factor \u03b1 antagonists vs vedolizumab in patients with inflammatory bowel diseases","volume":"20","author":"Singh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502396_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T01:37:44Z","timestamp":1763861864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570525000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0210570525000615"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502396","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-na\u00efve patients with ulcerative colitis: A comparative real-world multicentric observational study","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502396"}}